

Instance: composition-en-444c9ba43fa8be9df56ba30d3dc13ea7
InstanceOf: CompositionUvEpi
Title: "Composition for integrilin Package Leaflet"
Description:  "Composition for integrilin Package Leaflet"
Usage: #example

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - integrilin"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Integrilin is and what it is used for </li>
<li>What you need to know before you are given Integrilin </li>
<li>How to use Integrilin </li>
<li>Possible side effects </li>
<li>How to store Integrilin </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What integrilin is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What integrilin is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Integrilin is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from 
forming.  </p>
<p>It is used in adults with manifestation of severe coronary insufficiency defined as spontaneous and recent 
chest pain with electrocardiographic abnormalities or biological changes. It is usually given with aspirin 
and unfractionated heparin. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You must not be given Integrilin: </p>
<p>if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section 
6). </p>
<p>if you have recently had bleeding from your stomach, intestines, bladder or other organs, for 
example if you have seen abnormal blood in your stool or urine (except from menstrual bleeding) 
in the past 30 days. </p>
<p>if you have had a stroke within the past 30 days or any haemorrhagic stroke (also, be sure your 
doctor knows if you ever had a stroke). </p>
<p>if you have had a brain tumour or a condition that affects the blood vessels around the brain. </p>
<p>if you had a major operation or severe injury during the past 6 weeks. </p>
<p>if you have or have had bleeding problems. </p>
<p>if you have or have had difficulty with your blood clotting or a low blood platelet count. </p>
<p>if you have or have had severe hypertension (high blood pressure). </p>
<p>if you have or have had severe kidney or liver problems. </p>
<p>if you have been treated with another medicineof the same type as Integrilin. </p>
<p>Please tell your doctor if you have had any of these conditions. If you have any questions, ask your 
doctor or hospital pharmacist or nurse. </p>
<p>Take special care with Integrilin: </p>
<p>Integrilin is recommended for use only in adult, hospitalised patients in coronary care units. </p>
<p>Integrilin is not intended for use in children or adolescents less than 18 years of age. </p>
<p>Before and during your treatment with Integrilin, samples of your blood will be tested as a safety 
measure to limit the possibility of unexpected bleeding. 
During use of Integrilin, you will be checked carefully for any signs of unusual or unexpected 
bleeding. </p>
<p>Other medicines and Integrilin 
To avoid the possibility of interactions with other medicines please tell your doctor or hospital 
pharmacist or nurse if you are taking or have recently taken or might take any other medicines, 
including medicines obtained without a prescription. Particularly: </p>
<p>blood thinners (oral anticoagulants) or </p>
<p>medicines that prevent blood clots, including warfarin, dipyridamole, ticlopidine, aspirin (except 
those that you may be given as part of Integrilin treatment).  </p>
<p>Pregnancy and breast-feeding 
Integrilin is not usually recommended for use during pregnancy. Tell your doctor if you are pregnant, 
think you might be pregnant or are planning to have a baby. Your doctor will weigh up the benefit to 
you against the risk to your baby of using Integrilin while you are pregnant. </p>
<p>If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period. </p>
<p>Integrilin contains sodium </p>
<p>This medicine contains 161 mg sodium (main component of cooking/table salt) in each 100 ml 
vial. This is equivalent to 8.1% of the recommended maximum daily dietary intake of sodium 
for an adult. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Integrilin is given into the vein by direct injection followed by an infusion (drip solution). The dose 
given is based on your weight. The recommended dose is 180 microgram/kg administered as a bolus 
(rapid intravenous injection), followed by an infusion (drip solution) of 2 microgram/kg/minute for up to 
72 hours. If you have kidney disease, the infusion dose may be reduced to 1 microgram/kg/minute. </p>
<p>If percutaneous coronary intervention (PCI) is performed during Integrilin therapy, the intravenous 
solution may be continued for up to 96 hours. </p>
<p>You must also be given doses of aspirin and heparin (if not contraindicated in your case). </p>
<p>If you have any further questions on the use of this product, ask your doctor or hospital pharmacist or 
nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Very common side effects 
These may affect more than 1 in 10 people </p>
<p>minor or major bleeding, (for example, blood in urine, blood in stool, vomiting blood, or bleeding 
with surgical procedures). </p>
<p>anaemia (decreased number of red blood cells).  </p>
<p>Common side effects 
These may affect up to 1 in 10 people </p>
<p>inflammation of a vein. </p>
<p>Uncommon side effects 
These may affect up to 1 in 100 people </p>
<p>reduction in the number of platelets (blood cells necessary for blood clotting). </p>
<p>reduced blood flow to the brain. </p>
<p>Very rare side effects 
These may affect up to 1 in 10,000 people </p>
<p>serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the 
lungs). </p>
<p>fatal bleeding. </p>
<p>severe reduction in the number of platelets (blood cells necessary for blood clotting). </p>
<p>skin rash (such as hives). </p>
<p>sudden, severe allergic reaction. </p>
<p>If you notice any signs of bleeding, notify your doctor or hospital pharmacist or nurse immediately. Very 
rarely, bleeding has become severe and even fatal. Safety measures to prevent this from happening 
include blood tests and careful checking by the healthcare professionals taking care of you.  </p>
<p>If you develop severe allergic reaction or hives, notify your doctor or hospital pharmacist or nurse 
immediately. </p>
<p>Other events that may occur in patients, who require this type of treatment, include those that are 
related to the condition you are having treated, such as rapid or irregular heartbeat, low blood pressure, 
shock or cardiac arrest. </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor, hospital pharmacist or nurse. This includes any possible 
side effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store integrilin"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store integrilin"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children  </p>
<p>Do not use this medicine after the expiry date (EXP) stated on the package and the vial. The expiry date 
refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C   8 C). </p>
<p>Keep the vial in the outer package in order to protect from light. However, protection of Integrilin solution 
from light is not necessary during administration. </p>
<p>Before using, the vial contents should be inspected. 
Integrilin should not be used if it is noticed that particulate matter or discoloration is present.  </p>
<p>Any unused medicine after opening should be thrown away.   </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your hospital pharmacist how 
to throw away medicines you no longer use. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Integrilin contains </p>
<p>The active substance is eptifibatide. Each ml of solution for infusion contains 0.75 mg of 
eptifibatide. One vial of 100 ml of solution for infusion contains 75 mg of eptifibatide.  </p>
<p>The other ingredients are citric acid monohydrate, sodium hydroxide and water for injections. </p>
<p>What Integrilin looks like and contents of the pack 
Integrilin solution for infusion: 100 ml vial, pack of one vial.  </p>
<p>The clear, colourless solution is contained in a 100 ml glass vial, which is closed with a butyl rubber 
stopper and sealed with a crimped aluminium seal. </p>
<p>Marketing Authorisation Holder and manufacturer </p>
<p>Marketing Authorisation Holder: </p>
<p>GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland </p>
<p>Manufacturer: </p>
<p>GlaxoSmithKline Manufacturing S.P.A., Strada Provinciale Asolana No. 90, San Polo di Torrile 
43056, Parma, Italy </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
T l/Tel: + 32 (0) 10 85 52 Lietuva 
GlaxoSmithKline (Ireland) Limited<br />
Tel: +370 80000<br />
GlaxoSmithKline (Ireland) Limited 
 . +359 80018Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Belgique/Belgien 
T l/Tel: + 32 (0) 10 85 52  esk  republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 222 001 cz.info@gsk.com </p>
<p>Magyarorsz g 
GlaxoSmithKline (Ireland) Limited 
Tel.: +36 80088Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 dk-info@gsk.com </p>
<p>Malta 
GlaxoSmithKline (Ireland) Limited 
Tel: +356 80065Deutschland 
GlaxoSmithKline GmbH &amp; Co. KG 
Tel.: + 49 (0)89 36044 8produkt.info@gsk.com </p>
<p>Nederland 
GlaxoSmithKline BV 
Tel:  + 31 (0)33 2081Eesti 
GlaxoSmithKline (Ireland) Limited 
Tel: +372 8002Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20 <br />
GlaxoSmithKline   A.E.B.E. 
 : + 30 210 68 82  sterreich 
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com </p>
<p>Espa a 
GlaxoSmithKline, S.A. 
Tel: + 34 900 202 es-ci@gsk.com </p>
<p>Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (0)22 576 9France 
Laboratoire GlaxoSmithKline 
T l.: + 33 (0)1 39 17 84 diam@gsk.com </p>
<p>Portugal 
GlaxoSmithKline   Produtos Farmac uticos, Lda 
Tel: + 351 21 412 95 FI.PT@gsk.com </p>
<p>Hrvatska 
GlaxoSmithKline (Ireland) Limited 
Tel: +385 800787Rom nia 
GlaxoSmithKline (Ireland) Limited 
Tel: +40 800672Ireland 
GlaxoSmithKline (Ireland) Limited 
Tel: + 353 (0)1 4955Slovenija 
GlaxoSmithKline (Ireland) Limited 
Tel: +386 80688 sland 
Vistor hf. 
S mi: + 354 535 7Slovensk  republika 
GlaxoSmithKline (Ireland) Limited 
Tel: +421 800500Italia 
GlaxoSmithKline S.p.A. 
Tel: + 39 (0)45 7741 Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 (0)10 30 30 <br />
GlaxoSmithKline (Ireland) Limited 
 : +357 80070Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 info.produkt@gsk.com </p>
<p>Latvija 
GlaxoSmithKline (Ireland) Limited 
Tel: +371 80205United Kingdom (Northern Ireland) 
GlaxoSmithKline (Ireland) Limited 
Tel: + 44 (0)800 221customercontactuk@gsk.com 
This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

